BOTHELL, Wash.--(BUSINESS WIRE)--April 4, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today that it is reporting data on its SGN-70 program and proprietary antibody-drug conjugate (ADC) technology during six poster presentations at the 2006 Annual Meeting of the American Association for Cancer Research (AACR). The meeting is being held April 1-5, 2006, in Washington, DC.
